Biofil Chemicals & Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 27, 2025.
BIOFILCHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biofil Chemicals & Pharmaceuticals held its 40th AGM on September 27, 2025 via video conference, attended by 51 members out of 25,641 total shareholders. The meeting ran briefly from 3:02 PM to 3:17 PM, chaired by Mr. Ketan Shah (now Chairman & Managing Director). Eight resolutions were transacted, including adoption of FY25 audited financials, re-appointment of two independent directors (Mr. Ashok Kumar Ramawat and Mr. Satish Beohar) for a second five-year term, re-appointment of Mr. Meet Shah as director retiring by rotation, appointment of secretarial auditor, approval of material related party transactions with Cyano Pharma Private Limited, change in designation of Mr. Ketan Shah from Whole Time Director to Chairman and Managing Director, and confirmation of Mr. Smitesh Shah as promoter non-executive director. The statutory and secretarial auditors' reports contained no qualifications or adverse remarks. Voting was conducted via remote e-voting and e-voting during the AGM, with detailed results to be filed separately.
This is a routine procedural filing disclosing AGM proceedings. Voting results for all eight resolutions are pending and will be submitted separately under SEBI regulations — investors should wait for the voting outcome to assess shareholder approval on key items like the related party transaction with Cyano Pharma and leadership changes. No immediate material impact on the stock is expected from this disclosure alone.